Anti-inflammatory and antitumor activities of the chloroform extract and anti-inflammatory effect of the three diterpenes isolated from *Salvia ballotiflora* Benth

Nimsi Campos-Xolalpa¹, Ángel Josabad Alonso-Castro², Elizabeth Ortíz-Sanchez³, Juan Ramon Zapata-Morales², Marco Martin González-Chávez⁴ and Salud Pérez⁵*

**Abstract**

**Background:** Drugs used for the treatment of diseases associated with chronic inflammation, such as cancer and rheumatoid arthritis have the potential to cause undesirable side-effects, which might result in patients ending treatment prematurely. However, plants are a viable option for the treatment of inflammatory diseases. In this study, we assessed the in vivo and in vitro anti-inflammatory activity, and the antitumor effects of the chloroform extract of *Salvia ballotiflora* (ECL). The pro-apoptotic effects of ECL in CT26 cells were also determined.

**Methods:** The chloroform extract of *Salvia ballotiflora* (ECL) was standardized using 19-deoxyicetexone (DEOX) as a phytochemical marker. The anti-inflammatory activity of ECL was determined on acute and chronic inflammatory models using the TPA-induced mouse ear edema assay. The antitumor activity of ECL was evaluated by the subcutaneous inoculation of CT26 cells on the back of Balb/c mice. *In vitro* CT26 cell death induced by ECL was determined by Annexin V/propidium iodide staining assay using flow cytometry. ECL and the diterpenes isolated from the chloroform extract included 19-deoxyicetexone (DEOX), icetexone (ICT), and 7,20-dihydroanastomosine (DAM), which were tested in LPS-stimulated J774A.1 macrophages to quantify pro-inflammatory cytokine levels. The *in vitro* anti-arthritic activity of ECL was determined using the bovine serum protein (BSP) denaturation assay.

**Results:** ECL exerted anti-inflammatory activities in acute (84% of inhibition, 2 mg/ear) and chronic models (62.71%, at 100 mg/kg). ECL showed antitumor activity at 200 mg/kg and 300 mg/kg, reducing tumor volume by 30 and 40%, respectively. ECL (9.5 μg/mL) induced *in vitro* apoptosis in CT26 cells by 29.1% (48 h of treatment) and 93.9% (72 h of treatment). ECL (10 μg/ml) decreased levels of NO (53.7%), pro-inflammatory cytokines IL-6 (44.9%), IL-1β (71.9%), and TNF-α (40.1%), but increased the production of the anti-inflammatory cytokine IL-10 (44%). The diterpenes DEOX, ICT, and DAM decreased levels of NO (38.34, 47.63, 67.15%), IL-6 (57.84, 60.45, 44.26%), and TNF-α (38.90, 31.30, 32.83%), respectively. ECL showed *in vitro* antiarthritic activity (IC₅₀ = 482.65 μg/mL).

(Continued on next page)
Background
Inflammation is a complex biological response of the immune system to repair damage caused by injury including chemical, biological, physical, or mechanical agents [1]. Depending on its duration, inflammation can be acute or chronic. Acute inflammation is a beneficial response, whereas chronic inflammation can induce tissue damage [2]. Chronic inflammation can also lead to the progression of many diseases, such as rheumatoid arthritis and cancer [2].

Cancer is a process of uncontrolled cell growth that forms tumors and produces damage to surrounding tissues due to the inflammatory response. In most cases, premalignant lesions, inflammatory diseases, and cancer are treated with different types of drugs, however, most of these compounds cause severe side-effects [3]. Active compounds obtained from medicinal plants used in traditional medicine are considered alternative treatments for several diseases, including cancer and inflammatory-related diseases [4]. The Salvia genus, with more than 900 species, is composed of many plants with different biological activities including insecticidal, antifungal, cytotoxic, and anti-inflammatory, among others [5].

Salvia ballotiflora Benth (Lamiaceae), commonly known in Mexico as “mejorana”, is an endemic plant from Northern Mexico and the Southern United States of America used in folk medicine for baths during pregnancy [6]. From this plant species, two diterpene quinones have been isolated, icetexone (ICT) and conacytone [7] as well as other diterpenes, such as 19-deoxyicetexone (DEOX), 19-deoxyisocetexone (DIC), and 7,20-dihydroanstomosine (DAM), among others [8]. Other isolated compounds from Salvia ballotiflora include 7α-acetoxy-6,7-dihydroicetexone, and anastomosine, these two compounds have shown cytotoxic activity against the cancer cell lines U251 and SKLU-1, and an anti-inflammatory effect on acute ear edema induced by TPA in mice [9]. Additional, some studies have found that different diterpenes exhibited an important anti-inflammatory effect [10]. Recently, DEOX, DIC, and DAM were obtained from the hexane-washed chloroform extract of S. ballotiflora (ECL), and the cytotoxic activity of ECL was determined against the cancer cell lines A549, CT26, HeLa, and MCF7 [6]. These results show that S. ballotiflora and some of its metabolites have cytotoxic activity, and anti-inflammatory activity. However, there is not reports about the the anti-inflammatory effect of ECL, DEOX, DAM and ICT, mechanism of action, and the ECL effect on cancer tumor. For these reasons, we evaluated the anti-inflammatory effect in acute and chronic models and antitumor activities of ECL, including the anti-inflammatory effects in vitro of ECL and three of the isolated diterpenes (DEOX, ICT, and DAM). Lastly, the pro-apoptotic effects of ECL in CT26 cells were also determined.

Methods
Materials
Fetal bovine serum (FBS), Dulbecco’s Modified Eagle Medium (DMEM), antibiotics, 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), indomethacin (IND), diclofenac sodium (DICLO), polyvinylpyrrolidone (PVP), Griess reagent (GR), and 12-O-tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma Aldrich (St. Louis, MO, USA). The murine colorectal cancer cell line CT26 and the murine J774A.1 macrophages were purchased from ATCC (Manassas, VA, USA), whereas cisplatin (CDDP) was acquired from PISA Laboratory (PISA™ Pharmaceuticals, Guadalajara, Mexico).

Plant material
Salvia ballotiflora Benth was collected in Las Comadres, Municipality of Guadalcazar within the state of San Luis Potosi, Mexico in August 2017. A voucher specimen was preserved in the Isidro Palacios Herbarium of the Autonomous University of San Luis Potosi (SLPM43014). A taxonomist (José García Pérez) identified the plant material. S. ballotiflora is not an endangered species, and for this reason, a collection permit is not required by the Secretariat of Ecology and Environmental Management of San Luis Potosi (SEGAM-SLP).

Extract preparation
The dried and ground aerial parts (500 g) of S. ballotiflora were extracted with 3 L of chloroform at the boiling point for 4 h. The mixture was filtered and the solvent was evaporated to dryness under reduced pressure. The solid material was then washed with warm hexane (ECL) and a 5.07% yield was obtained.

Isolation of DEOX, ICT, and DAM
The diterpenes were isolated from ECL by open column chromatography using a mixture of hexane-ethyl acetate as described earlier [6].

**Conclusions:** ECL exhibited anti-inflammatory and anti-tumor activities. Furthermore, the diterpenes DEOX, DAM, and ICT showed anti-inflammatory activity by reducing levels of NO, TNF-α, and IL-6.

**Keywords:** Salvia ballotiflora, Anti-inflammatory activity, Antiarthritic activity, Antitumoral activity, Chloroform extract
Analysis by GC-MS
A mixture of 5 mg ECL or 1 mg DEOX, 1 mL of isooctane and 100 μL of bis(trimethylsilyl) trifluoroacetamide with 10% of trimethylsilyl chloride was heated at 100 °C for 30 min.

The ECL analysis was performed with a gas chromatography/mass spectrometer (Agilent Technology, model 6890 N) connected to a mass detector model 5973 with a DB-5HT capillary column. The injector temperature was set at 200 °C. The initial oven temperature (250 °C) was held for 2 min, then the temperature was increased at a rate of 15 °C/min up to 325 °C and maintained for 3 min. The splitless injection was performed at a ratio of 1:100 and the injector temperature was 325 °C. The spectrum was determined at 70 eV. DEOX was identified in ECL and extrapolation of this diterpene was performed on the standard curve (500–31 ppm). We use DEOX for the extract standardization because this diterpene is the most abundant of the three diterpenes in ECL [6].

Animals
One hundred fifty-two Male CD1 and forty-eight Balb/c mice (20–25 g, 6–7 weeks of age) from the animal facility of the Autonomous Metropolitan-Xochimilco University, were used. The experimental protocol (140) was approved by the Research Bioethics Committee of the Autonomous Metropolitan-Xochimilco University. All experiments were performed in compliance with the Mexican Official Norm for Animal Care and Handling (NOM-062-ZOO-1999). Mice were maintained with free access to food (Lab Diet 5001) and water ad libitum. Animals were housed at 24 °C ± 1 °C with 12 h light/dark access to food (Lab Diet 5001) and water ad libitum. An-...
5 μg/mL LPS. After 2 h, cells were treated with ECL (10 μg/mL), DAM and ICT (25 μg/mL), DEOX (20 μg/mL), or reference drug (IND 17.1 μg/mL), and (culture medium with vehicle only). After 24 h, supernatants were collected for the quantification of NO and levels of IL-1β, IL-6, IL-10, and TNF-α, using commercial enzyme-linked immunosorbent assays (ELISA), following the manufacturer’s instructions (PROMEGA). The absorbance was recorded at 405 nm. For the quantitation of NO production, 100 μL of supernatant was mixed with 100 μL of Griess reagent in a 96-well plate. The reaction mixture was incubated at 37°C for 30 min and the absorbance was measured at 540 nm with an ELISA reader (Bio-Rad). A 100% nitric oxide production was considered for the LPS group [15].

Membrane stabilization property

Blood samples were collected, maintaining aseptic conditions, from healthy human volunteers that did not consume non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or oral contraceptives for 2 weeks prior to the experiment. Blood samples were washed with an equal volume of Alsever solution (2% dextrose, 0.8% sodium citrate, 0.05% citric acid, and 0.42% sodium chloride in water), and centrifuged at 3000 rpm for 10 min; then packed cells were washed three times with Alsever solution.

A 5% erythrocyte suspension was mixed with different concentrations (25–400 μg/mL) of ECL or DICLO prepared in PBS buffer. Distilled water and PBS buffer were used as negative controls. All samples were incubated at 37°C for 30 min and centrifuged at 3500 rpm for 5 min [16]. The optical density was read at 450 nm. The percent protection was calculated with the following equation:

\[
\% \text{Protection} = 100 - \left( \frac{\text{optical density of Test sample}}{\text{optical density of Control}} \right) \times 100
\]

In vitro anti-arthritis activity

The bovine serum protein (BSP) denaturation method [17] was used to evaluate in vitro anti-arthritis activity. A BSP solution (5% w/v aqueous solution) was prepared as follows: 0.45 mL of BSP solution and 0.05 mL of the drug treatment. The ECL concentrations were 25, 50, 100, 200, 500, 750, and 1000 μg/mL and the DICLO treatment included the same concentrations as ECL, and distilled water was used as a control. Samples were heated at 37°C for 20 min and the temperature was increased to 57°C for 3 min. After cooling, 2.5 mL PBS was added to the solutions. The absorbance was measured at 560 nm. The control represents 100% protein denaturation. The percentage of protein denaturation inhibition was estimated as follows:

\[
\% \text{of protein denaturation inhibition} = 100 - \left( \frac{\text{Optical density of Test} - \text{Optical density of Control}}{\text{Optical density of Test}} \right) \times 100
\]

Aptosis assay

CT26 cells were seeded in 100 mm² culture plates (2 × 10⁶ cells/plate). After 24 h, cells were incubated with CDDP (1.4 μg/mL), ECL (9.5 μg/mL), or DMSO at a final concentration of 0.01% (vehicle group). After treatment (48 h or 72 h), cells were detached with EDTA solution in 1X PBS, washed and centrifuged at 4500 rpm for 5 min. Cells were stained with the Annexin V/propidium iodide kit (Dead Cell Apoptosis Kit with Annexin V FITC and PI, for flow cytometry. Invitrogen) and read in a FacScan flow cytometer (BD Bioscience, USA). Data from 20,000 acquired events were analyzed using the Weasel cytometry analysis software v.2.6.1.

Antitumor assay

Bab/c mice were injected subcutaneously in their backs with CT26 cells (6.5 × 10⁵) [18]. Eight days later, groups of 8 tumor-bearing mice (volume of 50 to 100 mm³) received oral doses of ECL (100, 200, and 300 mg/kg), dissolved in saline solution with PVP (1:4), 1 mg/kg CDDP (p.o. and i.p.) for 22 days, or 0.1 mL of saline solution. Tumors were measured using a Vernier, and size (in mm³) was calculated as follows:

\[
\text{Tumor volume} = \frac{\text{length} \times \text{width} \times \text{height}}{2}
\]

At the end of the experiments, animals were sacrificed in a CO₂ chamber, and tumors were excised and weighed.

Statistical analysis

Data are expressed as the mean ± S.E.M. When indicated, Student’s t-test and ANOVA followed by Dunnett’s test, were used. A P < 0.05 was considered significant. Results were processed using the SPSS software from IBM.

Results

Analysis by GC-MS

ECL was standardized using DEOX as a phytochemical marker. The calibration curve was linear from 31 to 500 ppm (R² = 0.9933). The results showed that ECL contains 0.2 mg/g (0.02%) of DEOX.

Acute toxicity test

Animals administered with ECL at doses of 625, 1250, 2500, and 5000 mg/kg showed a lethal dose (LD₅₀) higher than 5000 mg/kg; however, ECL at doses of 625 mg/kg showed visible damage in the kidneys, spleen, stomach, and liver of mice. ECL at 400 mg/kg showed
no visible damage to organs. Therefore, doses lower than 400 mg/kg ECL were used for subsequent studies.

**Anti-inflammatory activity of ECL in a mouse model of TPA-induced ear edema**

The anti-inflammatory activity of ECL was evaluated on acute TPA-induced ear edema in mice at doses of 2 mg/ear of indomethacin (IND) or ECL. The extract significantly inhibited inflammation by 84.79 ± 4.07%, with similar activity to IND (89.16 ± 6.4%). No significant differences (n = 8, p > 0.05) were shown between ECL and IND.

**Anti-inflammatory activity of ECL in mouse ear edema induced by multiple applications of TPA**

The chronic anti-inflammatory activity of ECL was evaluated in a model of multiple applications of TPA. ECL showed dose-dependent anti-inflammatory activity (ED50 = 45.33 mg/kg). ECL at doses of 12.5 mg/kg (26.43%) and 25 mg/kg (30.07%), showed low anti-inflammatory action, whereas ECL at doses of 50 mg/kg (53.28%) and 100 mg/kg (62.71%) presented a comparable anti-inflammatory effect to IND (8 mg/kg) (64.32%). These results show that ECL exerts an anti-inflammatory activity in a 9-day assay (Table 1).

**Cell viability in macrophages**

The IC50 values were as follows: 16.97 ± 2.04 μg/mL (ECL); 116.17 ± 7.33 μg/mL (DAM); 114.97 ± 7.09 μg/mL (ICT), and 54.57 ± 2.85 μg/mL (DEOX). Then, we used concentrations of the extract and compounds that did not affect 60% cell viability of J774A.1 macrophages (Fig. 1a). Therefore, we used 10 μg/mL ECL, 25 μg/mL DAM and ICT, and 20 μg/mL DEOX in subsequent experiments.

**Determination of NO levels**

Figure 1b shows the percentage of NO produced by macrophages stimulated with LPS and treated with ECL, DAM, ICT, or DEOX. The findings showed that ECL, DAM, ICT, and DEOX inhibited NO production by 56.74, 61.66, 52.37, and 32.85%, respectively. The reduction in NO levels by ECL and DAM was similar to the reference drug, 17.1 μg/mL IND (60.41%). However, DAM and ICT showed a low effect on NO inhibition.

**Levels of inflammatory cytokines**

The production of pro-inflammatory (IL-6, TNF-α, and IL-1β) and anti-inflammatory (IL-10) cytokines was assessed in LPS-stimulated macrophages treated with ECL (Fig. 2). In addition, IL-6 and TNF-α levels were determined in the presence of DAM, ICT, and DEOX (Fig. 2a, b).

ECL diminished the production of the pro-inflammatory cytokines by 71.9% for IL-1β. ECL, DAM, ICT, and DEOX inhibited the production of IL-6 by 44.9, 57.84, 60.45, and 44.26%, respectively, and of TNF-α by 40.1, 38.90, 31.30, and 32.83%, respectively. In addition, ECL increased the production of the anti-inflammatory cytokine IL-10 by that more 80%, with similar activity induced by IND (17.1 μg/mL).

**Membrane stabilization properties**

The in vitro anti-inflammatory activity of ECL was determined using the human red blood cell (HRBC) membrane stabilization method [16]. ECL evaluated at 25, 50, 100, 200, and 400 μg/mL showed membrane protection by 85.13 ± 0.16%, 87.52 ± 0.16%, 89.37 ± 0.37%, 90.97 ± 0.33%, and 91.078 ± 0.13% respectively. The IC50 value was 0.144 ± 0.0038 μg/mL. The results obtained with ECL were comparable to those obtained with DICLO at concentrations of 25, 50, 100, 200, and 400 μg/mL, which showed membrane stabilization in 89.71 ± 0.29%, 91.64 ± 0.31%, 92.10 ± 0.63%, 94.82 ± 0.17%, and 96.60 ± 0.21%, respectively. The IC50 value was 0.138 ± 0.0003 μg/mL.

**In vitro anti-arthritic activity**

The percentages of inhibition of bovine serum protein denaturation induced by ECL and DICLO are shown in Table 2. ECL presented antiarthritic activity in a concentration-dependent manner. DICLO, at the same concentrations, diminished protein denaturation (Table 2). The in vitro anti-arthritic activity effect of ECL (IC50 = 482.65 ± 12.67 μg/mL) was lower in comparison to DICLO (IC50 = 123.39 ± 14.65 μg/mL).

**ECL induces apoptosis in CT26 cells**

Apoptosis as a biological effect of ECL was evaluated in murine colon carcinoma CT26 cells. Flow cytometry assays showed that 29.1% of CT26 cells were in apoptosis after 24 h of ECL treatment (Fig. 3a). Furthermore, higher levels of apoptosis in CT26 cells were found after 72 h of treatment (93.3%), compared to the CDDP treatment (Fig. 3b), used as a positive treatment control (80.5%).
Antitumor assay
The antitumor activity of ECL was evaluated in Balb/c mice bearing CT-26 tumor for 22 days. The tumor volume from the vehicle group showed the largest tumor size among the experimental groups (2647.73 ± 464.48 mm³). ECL at doses of 200 mg/kg (1569.88 ± 386.70 mm³) and 300 mg/kg (1618.87 ± 295.70 mm³) decreased tumor volume in a similar pattern as with 1 mg/kg CDDP p.o. (1531.20 ± 236.80 mm³) (Fig. 4).

At the end of the treatment, tumors from the vehicle group were the heaviest (6.01 g). ECL decreased tumor weight or in a dose-dependent manner: 100 mg/kg (34.86%), 200 mg/kg (38.14%), and 300 mg/kg (51.10%). The reference drug, 1 mg/kg CDDP p.o. decreased tumor weight by 57.09% (Table 3). ECL showed a ED₅₀ of 291.51 mg/kg.

Discussion
We found that the yield of DAM, ICT, and DEOX was lower than 0.005% [6], and as a result, only few experiments with these compounds were performed [9]. Therefore, the in vivo models, quantitation of IL-1β and IL-10 in LPS-stimulated macrophages, anti-arthritic activity, membrane stabilization assay, the apoptosis and the antitumor assay were assessed only with ECL standardized with DEOX as the phytochemical marker.

This study shows for the first time, the anti-inflammatory activity of the extract and the three diterpenes, and the antitumor effect of the extract. ECL presented in vivo anti-inflammatory activities in both acute and chronic assays. ECL diminished mouse acute TPA-induced ear edema by 84.79%, with a similar activity compared to IND treatment (89.16%). The inflammation produced by topical applications of TPA is mediated by protein kinase C, the formation of reactive oxygen species, prostaglandins, and the production of phospholipase A₂ [19]. Therefore, a strategy used to control inflammation is the inhibition of some of these inflammatory mediators. According to the results, ECL
reduced acute and chronic inflammation induced by TPA. This indicates that ECL might inhibit the production of inflammatory mediators. The chronic TPA-induced mouse ear edema is caused by the production of infiltrating leukocytes, which eventually causes tissue damage [20]. ECL at 100 mg/kg showed a reduction (62.71%) of chronic TPA-induced mouse ear edema with activity comparable to the IND positive control group (64.32%). These findings clearly indicate that ECL exerts in vivo anti-inflammatory activity.

**Table 2 In vitro anti-arthritic activity of ECL using the bovine serum protein denaturation method**

| Group | Concentration (μg/mL) | % denaturation | % Inhibition of denaturation |
|-------|-----------------------|----------------|-----------------------------|
| Control | –                     | 100            | 0                           |
| DICLO  | 1000                  | 9.85 ± 2.80    | 90.15 ± 2.81                |
|        | 750                   | 25.63 ± 7.29   | 74.37 ± 7.29                |
|        | 500                   | 33.27 ± 0.01   | 66.73 ± 0.01                |
|        | 200                   | 42.04 ± 4.09   | 57.96 ± 4.09                |
|        | 100                   | 51.90 ± 2.79   | 48.10 ± 2.79                |
|        | 50                    | 61.58 ± 0.26   | 38.42 ± 0.26                |
|        | 25                    | 65.89 ± 0.01   | 34.11 ± 0.01                |
| ECL    | 1000                  | 27.00 ± 6.61   | 72.99 ± 6.61                |
|        | 750                   | 42.20 ± 4.07   | 57.79 ± 4.07                |
|        | 500                   | 49.32 ± 2.75   | 50.67 ± 2.75                |
|        | 200                   | 54.60 ± 4.35   | 45.39 ± 4.35                |
|        | 100                   | 61.38 ± 3.11   | 38.61 ± 3.11                |
|        | 50                    | 65.82 ± 3.03   | 34.17 ± 3.03                |
|        | 25                    | 70.16 ± 0.10   | 29.84 ± 0.10                |

The values are the mean ± S.E.M of three independent experiments.
Fig. 3 CT26 cells were incubated for 48 h (a) and 72 h (b) treated with vehicle (DMSO 0.01%), CDDP (1.4 μg/mL) and ECL (9.5 μg/mL). The apoptosis assay with Annexin V and Propidium Iodide was used, recording 20,000 events. The percentage of cells in each quadrant is found in the corner. The cells in the right quadrants (Annexin V+/PI– and Annexin V+/PI+) are considered as apoptotic cells. Data are representative of three independent experiments.

Fig. 4 Tumor volume (mm³) during 22 days of treatment. Data were expressed as mean ± s.e.m. (n = 8). Data were expressed as mean ± S.E.M. Values were significantly different compared with the (*) vehicle and (#) CDDP p.o. group using the Dunnett’s test: *p < 0.05
cytokines, such as IL-1β, increases in cell migration.

ICT inhibited NO production, which suggests a decrease in neutrophil migrations, which is associated with the inhibition of NO release. Cezarotto and collaborators [25] found that ICT diminished neutrophil migrations, which is associated with the inhibition of NO release. Cezarotto and collaborators [25] found that ICT diminished neutrophil migrations, which is associated with the inhibition of NO release.

During the inflammatory process, there is an increase in vascular permeability and cell migration, such as macrophages and neutrophils, which are related to the synthesis of prostaglandins and cytokines, and the increase of NO release. Cezarotto and collaborators [25] found that ICT inhibited neutrophil migrations, which is associated with its anti-inflammatory activity. We found that ICT inhibited NO production, which suggests a decrease in cell migration.

During the inflammatory process, the production of cytokines, such as IL-1β, IL-6, and TNF-α by macrophages occurs to repair damaged tissues [1]. TNF-α, a cytokine involved in acute inflammatory processes, regulates the levels of other pro-inflammatory cytokines like IL-6, which is involved in the induction and perpetuation of early inflammation [26]. IL-1β is another pro-inflammatory cytokine that plays an important role in host-defense responses against injury induced by infections and pain progression [27]. IL-1β increases tissue damage during chronic diseases [28]. IL-10 is an anti-inflammatory cytokine that limits the host immune response by preventing damage to the host and contributing to the maintenance of tissue homeostasis [1]. Thus, the inhibition of pro-inflammatory cytokines (IL-1, IL-6, and TNF-α), and the increase in the production of the anti-inflammatory cytokine IL-10 by ECL, may be an effective strategy in the treatment of inflammatory conditions. DAM, ICT, and DEOX also diminished IL-6 and TNF-α levels, which suggests that the anti-inflammatory activity is due to these diterpenes. ECL significantly increased IL-10 production with similar activity in comparison with IND.

The hypotonic solution exerts hemolytic effects related to fluid accumulation in cells and the subsequent breaking of cell membranes. Compounds with membrane-stabilizing effects might inhibit phospholipase production by diminishing the levels of some inflammatory mediators [29]. The erythrocyte membrane is analogous to the liposomal membrane and the prevention of hypotonicity-induced HRBC membrane lysis is a direct measurement of the anti-inflammatory effect of drugs [30]. ECL showed a high effect (IC₅₀ = 0.144 ± 0.0038 µg/mL) on membrane-stabilization of erythrocytes. This effect was comparable to DICLO (IC₅₀ = 0.138 ± 0.0003 µg/mL). Therefore, this extract may act as a potent anti-inflammatory agent.

Rheumatoid arthritis is one of the most common inflammatory diseases with an increasing incidence worldwide. During the development of this disease, protein denaturation occurs, resulting in the formation of autoantigens and the consequent development of joint inflammation [31]. In this study, ECL decreased heat-induced protein denaturation, suggesting that ELC could exert anti-arthritis activity.

Persistent inflammation can cause DNA damage, leading to the initiation and progression of cancer [32]. Chronic inflammation is caused by the constant activation of the immune system, which inevitably results in the accumulation of genetic and epigenetic aberrations, and the subsequent malignant transformation, also induced by the participation pro-inflammatory cytokines, transcription factors, tumor suppressor genes, and oncogenes [33]. These findings might suggest that ECL could be used as an anti-inflammatory and antitumor agent, since this extract decreases in vivo chronic inflammation.

Chemotherapy relies on the inhibition of proliferation and the induction of apoptosis in cancer cells [34]. Apoptosis is the process of programmed cell death, considered an important component of various processes, including normal cell turnover, proper development and functioning of the immune system, embryonic development, chemical-induced cell death, cell growth, and cytoskeletal rearrangement [35]. Alterations in apoptosis cause neurodegenerative diseases, ischemic damage, autoimmune disorders, and many types of cancer [36]. At 72 h of treatment, ECL induced apoptosis in CT26

| Study groups       | Tumor weight (g) | % of weight decrease |
|--------------------|-----------------|----------------------|
| Vehicle            | 6.01 ± 0.99 *   | 0 *                  |
| CDDP (1 mg/Kg) i.p.| 1.25 ± 0.59 *   | 79.21 * #            |
| CDDP (1 mg/Kg) p.o.| 2.58 ± 0.42 *   | 57.09 *              |
| ECL 100 mg/Kg p.o. | 3.92 ± 0.68 *   | 34.86 * #            |
| ECL 200 mg/Kg p.o. | 3.72 ± 0.65 *   | 38.14 * #            |
| ECL 300 mg/Kg p.o. | 2.94 ± 0.55 *   | 51.10 *              |

Data were expressed as mean ± S.E.M. (n = 8). Values were significantly different compared with the (*) vehicle and (#) CDDP p.o. group using the Dunnett’s test: *p < 0.05.
cancer cells with similar activity as with CDDP, the reference drug. Previously, it was found that ECL exerted cytotoxic activity on CT26 cells and other cancer cell lines [6]. Tumor suppression is a hallmark of cancer progression [33]. In this work, ECL showed the ability to induce in vitro apoptosis in CT26 cells and reduce the growth of tumors in Balb/c mice bearing CT26 tumors. Since ECL decreased tumor growth in mice, this effect was similar to that obtained when the animals were orally administered with CDDP. Then, it is possible that ECL might inhibit proliferation of CT26 cells. Therefore, ECL may be a potential cytotoxic and antitumor agent in the treatment of colorectal cancer. The anti-inflammatory activity of natural products is related to their cytotoxic and antitumor actions [37]. In this context, ECL as well as DAM, ICT, and DEOX could be considered important candidates for the treatment of inflammatory diseases and cancer.

Conclusion
For the first time, ECL has shown in vitro and in vivo anti-inflammatory effects and in vitro anti-arthritic activities. ECL induced apoptosis in CT26 cells and showed antitumor activity. In LPS-stimulated macrophages, ECL, DAM, ICT, and DEOX inhibited the production of NO, and decreased pro-inflammatory cytokine levels. Furthermore, ECL increased the levels of the anti-inflammatory cytokine IL-10. ECL is a protective agent against both membrane lysis and protein denaturation.

Abbreviations
ECL: Chloroform extract of S. ballotiflora; ICT: Icetexone; DEOX: 19-deoxyicetoxone; DIC: 19-deoxyicetoxone; DAM: 7,20-dihydrocanastomosine; FBS: Fetal bovine serum; DMEM: Dulbecco Modified Eagle Medium; MTT: Antibiotics, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; IND: Indomethacin; DICLO: Diclofenac sodium; PVP: Polyviylnylpyrolidone; GR: Griess reagent; TPA: 12-O-tetradecanoylphorbol-13-acetate; CT26: The murine colorectal cancer cell line; J774A.1: The murine macrophages cell line; IL-1, IL-6, IL-10: Interleukin 1, 6, and 10; TNF-α: Tumor necrosis factor-α; CDDP: Cisplatin; IC50: Half maximal inhibitory concentration; NO: Nitric oxide; ED50: Median effective dose

Acknowledgements
Nimis Campos Xolalpa, M.S in Pharmaceutical Sciences, thanks the Consejo Nacional de Ciencia y Tecnologia (CONACyT) for financial support and the granted scholarship 326997 to perform PhD studies in Doctorado en Ciencias Biologicas y de la Salud at UAM-Xochimilco, Mexico.

Authors’ contributions
Conceptualization, S.P.G., A.J.A.C., E.O.S. and N.C.X.; Methodology, N.C.X., A.J.A.C., E.O.S., S.P.G., MM.G.C. and J.R.Z.M.; validation, N.C.X.; formal analysis, E.O.S., J.R.Z.M. and N.C.X.; investigation, N.C.X., MM.G.C., E.O.S.; resources, A.J.A.C., E.O.S. and S.P.G.; data curation, N.C.X., A.J.A.C., E.O.S., S.P.G., MM.G.C. and J.R.Z.M.; writing—original draft preparation, N.C.X., A.J.A.C., E.O.S., and S.P.G.; writing—review and editing, A.J.A.C., E.O.S. and S.P.G.; visualization, A.J.A.C., E.O.S. and S.P.G.; supervision, A.J.A.C., E.O.S. and S.P.G.; funding acquisition A.J.A.C., E.O.S. and S.P.G. All authors have read and agreed to the published version of the manuscript.

Funding
Not applicable.

Availability of data and materials
The data associated with this study is available from corresponding author.

Ethics approval and consent to participate
The current study was approved by the Internal Committee for the Care and Use of Laboratory Animals. UPBEL-Biotério, Project number 140, Division of Biological and Health Sciences. Autonomous Metropolitan-Xochimilco University.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests in this article.

Author details
1Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud, Delegación Coyoacán, CP 04960 Ciudad de México, Mexico. 2Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Noria Alta S/N C.P, 36050 Guanajuato, GTO, Mexico. 3Instituto Nacional de Cancerología, Subdirección de Investigación Básica, Av. San Fernando 22, Belisario Domínguez, 14080 CDMX, CO, Mexico. 4Centro de Investigación y Estudios de Posgrado, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, Zona Universitaria, 78210 San Luis Potosí, SLP, Mexico. 5Department of Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Col. Villa Quietud, Delegación Coyoacán, CP 04960 Ciudad de México, Mexico.

Received: 29 September 2020 Accepted: 7 December 2020
Published online: 07 January 2021

References
1. Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Molecular pharmacology of inflammation: medicinal plants as anti-inflammatory agents. Pharmacol Res Pharmaccol. 2019;139:126–40.
2. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–82.
3. Bidram E, Esmaeili Y, Ranji-Burachaloo H, Al-Zaibai N, Zarabi A, Stewart A, Dunstan DE. A concise review on cancer treatment methods and delivery systems. J Drug Deliv Sci Tec. 2019;54:101350.
4. Khan RA. Natural products chemistry: the emerging trends and prospective goals. Saudi Pharm J. 2018;26(5):739–53.
5. Sharifi-Rad K, Ozcelik B, Alitin G, Daşkaya-Dikmen C, Martorell M, Ramírez-Alarcón K, Alarcón-Zapata P, Moraí-Braga MFB, Carreño JNP, Borges-Leal ALA, Melo-Coutinho HD, Gayvali R, Tahergorabi R, Ibrahim SA, Sahri-Rad R, Sharoppov F, Salehi B, Contreras MM, Segura-Carretero A, Sen S, Acharya K, Sharifi-Rad J. Salvia spp. plants from farm to food applications and phytopharmacotherapy. Trends Food Sci. Technology. 2018;80:242–63.
6. Campos-Xolalpa N, Alonso-Castro AJ, Sánchez-Mendoza E, Zavala-Sánchez MA, Pérez-Gutierrez S. Cytotoxic activity of the chloroform extract and four diterpenes isolated from Salvia ballotiflora. Rev Bras Farmacol. 2017;27(3): 302–5.
7. Taira Z, Watson WH, Domínguez XA. Structure of icerpenone, a diterpene quinone from Salvia ballotiflora. J Chem Soc Perk T 2. 1976(14):1278–30.
8. Esquível B, Calderón JS, Flores E, Sanchez AA, Rosas R. Abietane and iceritane diterpenoids from Salvia ballotaeflora and Salvia axilaris. Phytochemistry. 1997;46(3):531–4.
9. Esquível B, Bustos-Brito C, Sánchez-Castellanos M, Nieto-Camacho A, Ramírez-Apan T, Joseph-Nathan P, Quijano L. Structure, absolute configuration, and antiproliferative activity of abietane and iceritane diterpenoids from Salvia ballotaeflora. Molecules. 2017;22(10):1690.
10. Sala AW, Rodjun a, Karala IC, Ponglimanon C, Chantaprromma S, Kanjana-Opas a, Tevtrakul S, Fau HK. Potential anti-inflammatory diterpenes from Premna obtusifolia. Tetrahedron. 2012;68:819–29.
11. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol Arch Toxicol. 1983;44(4):275–87.
12. Young LM, Khefets JB, Ballaron SJ, Young JM. Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacological agents. Agents Actions. 1989; 26(3):335–41.
13. Stanley P-L, Steiner S, Havens M, Tramposch KM. Mouse skin inflammation induced by multiple topical applications of 12-O-Tetradecanoylphorbol-13-acetate. Skin Pharmacol Physiol. 1991;4(4):262–71.

14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods/Immunol Methods. 1983;65:55–63.

15. Sun J, Zhang X, Boderick M, Fein H. Measurement of nitric oxide production in biological systems by using Griess reaction assay. Sensors. 2003;3(8):276–84.

16. Parameswaran P, Devika R, Vijayaraghavan P. In vitro anti-inflammatory and antimicrobial potential of leaf extract from *Artemisia nilgirica* (Clarke) Pamp. Saudi J Biol Sci. 2019;26(3):460–3.

17. Hasan UH, Uttra AM, Rasool S. Evaluation of *in vitro* and *in vivo* anti-arthritis potential of *Berberis calliobotrys*. Bangl J Pharmacol. 2015;10(4):807–19.

18. Zhu L, Cao J, Qu M, Liu N, Zhang Y, Fleming C, Hu X, Zhang H. *Ca Y*, *Xue F*, *Quan C*, *Liu N*, *Zhang Y*, *Fleming C*, *Hu X*, *Zhang H*. *Parameswaran N*, *Patial S*. Tumor necrosis factor-α. Sens Translation. 2017;10:86–93.

19. Fuller B. Role of PGE-2 and other inflammatory mediators in skin aging and their inhibition by topical natural anti-inflammatories. Cosmet. 2019(6):1.6.

20. Kumar D. Molecular biology of acute and chronic inflammation. In: Kumar D, editor. Clinical Molecular Medicine. London: Academic Press. Elsevier Inc; 2015. p. 389–402.

21. Chen Y, Kam CS, Liu FQ, Liu Y, Lui VC, Lamb JR, Tam PK. LPS-induced up-regulation of TGF-β receptor 1 is associated with TNF-α expression in human monocyte-derived macrophages. J Leukoc Biol. 2008;83(5):1165–73.

22. Gu Q, Yang H, Shi Q. Macrophages and bone inflammation. J Orthop Translation. 2017;10:86–93.

23. Kollos G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113(4):427–37.

24. Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140(6):935–50.

25. Cezarotto CS, Dorneles A, Baldissera FG, da Silva MB, Markoski MM, Rodrigues-Junior LC, Peres A, Fazolo T, Bordignon SAL, Apel MA, Torres Romão PR, von Poser GL. Leishmanicidal antichemotactic activities of icetexanes from *Salvia uliginosa* Benth. Phytomedicine. 2019;58:152748.

26. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukar Gene. 2010;20(2):87–103.

27. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503–11.

28. Ca Y, Xue F, Quan C, Gu M, Liu N, Zhang Y, Fleming C, Hu X, Zhang H. *Ca Y*, *Xue F*, *Quan C*, *Gu M*, *Liu N*, *Zhang Y*, *Fleming C*, *Hu X*, *Zhang H*. *Wheatlembum R*, *Fu Y*, *Tieri D*, *Rouchka EC*, *Zheng J*, *Yan J*. A critical role of the IL-1β–IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139(1):146–56.

29. Rahman H, Eswaraiah MC, Vakati K, Madhavi P. Anti-tumor and immunomodulatory activities of an exopoly saccharide from *Rhizopus nigricans* on CT26 tumor-bearing mice. Int Immunopharmacollnt Immunopharmacol. 2016;36:118–24.

30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods/Immunol Methods. 1983;65:55–63.

31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods/Immunol Methods. 1983;65:55–63.

32. Jiangjiang QIN, Wei NG, Zhang R. Novel natural product therapeutics targeting both inflammation and cancer. Chin J Nat Med. 2017;15(6):401–16.

33. Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J Environ Res Public Health. 2013;10(9):3886–907.

34. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res Exp Cell Res. 2002;256(1):42–9.

35. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res Clin Cancer Res. 2000;6(2):681–90.

36. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.

37. Yang B, Xiao B, Sun T. Antitumor and immunomodulatory activity of *Astragalus Membranaceus* polysaccharides in H22 tumor-bearing mice. Int J Biol Macromol J Biol Macromol. 2013;62:287–90.

---

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.